PLUS THERAPEUTICS, INC.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
CNSY$0.68+19.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity/(Deficit
(In thousands, except share data)
| Convertible · Additional · Total | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| preferred stock · Common stock · Treasury Stock · paid-in · Accumulated · stockholders’ | |||||||||||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · (deficit)/equity | |||||||||||||||||||||
| Balance at December 31, 2023 | 1,952 | $ | — | 4,522,656 | $ | 5 | (78,559) | $ | (126) | $ | 479,274 | $ | (480,501) | $ | (1,348) | ||||||
| Stock-based compensation | — | — | — | — | — | — | 146 | — | 146 | ||||||||||||
| Purchase of treasury stock | — | — | — | — | (179,866) | (374) | — | — | (374) | ||||||||||||
| Net loss | — | — | — | — | — | — | — | (3,261) | (3,261) | ||||||||||||
| Balance at March 31, 2024 | 1,952 | $ | — | 4,522,656 | $ | 5 | (258,425) | $ | (500) | $ | 479,420 | $ | (483,762) | $ | (4,837) | ||||||
| Issuance of common stock | — | — | 1,439,988 | 1 | — | — | — | — | 1 | ||||||||||||
| Stock-based compensation | — | — | — | — | — | — | 151 | — | 151 | ||||||||||||
| Net loss | — | — | — | — | — | — | — | (2,940) | (2,940) | ||||||||||||
| Balance at June 30, 2024 | 1,952 | $ | — | 5,962,644 | $ | 6 | (258,425) | $ | (500) | $ | 479,571 | $ | (486,702) | $ | (7,625) | ||||||
| Balance at December 31, 2024 | 1,952 | $ | — | 6,154,758 | $ | 6 | (258,425) | $ | (500) | $ | 485,024 | $ | (493,479) | $ | (8,949) | ||||||
| Stock-based compensation | — | — | — | — | — | — | 148 | — | 148 | ||||||||||||
| Exercise of pre-funded warrants | — | — | 6,535,731 | 7 | — | — | (7) | — | — | ||||||||||||
| Exercise of Series B Warrants from May 2024 PIPE | — | — | 497,824 | — | — | — | 882 | — | 882 | ||||||||||||
| Exchange of warrants for notes payable | — | — | — | — | — | — | (3,694) | — | (3,694) | ||||||||||||
| Issuance of common stock, pre-funded warrants and warrants for debt repayment | — | — | 4,069,738 | 4 | — | — | 5,369 | — | 5,373 | ||||||||||||
| Net loss | — | — | — | — | — | — | — | (17,401) | (17,401) | ||||||||||||
| Balance at March 31, 2025 | 1,952 | $ | — | 17,258,051 | $ | 17 | (258,425) | $ | (500) | $ | 487,722 | $ | (510,880) | $ | (23,641) | ||||||
| Stock-based compensation | — | — | — | — | — | — | 152 | — | 152 | ||||||||||||
| Exercise of March 2025 Series B Warrants | — | — | 56,277,032 | 56 | — | — | 802 | — | 858 | ||||||||||||
| Exercise of pre-funded warrants | — | — | 9,016,349 | 9 | — | — | (9) | — | — | ||||||||||||
| Cancellation of common stock | — | — | (300,000) | — | — | — | — | — | — | ||||||||||||
| Issuance of common stock under Lincoln Park Purchase Agreement, net issuance costs | — | — | 10,187,000 | 10 | — | — | 2,736 | — | 2,746 | ||||||||||||
| Reclassification of 2025 Series B warrant liability to equity | — | — | — | — | — | — | 10,967 | — | 10,967 | ||||||||||||
| Modification of warrants (Note 12) | — | — | — | 6,801 | — | 6,801 | |||||||||||||||
| Net income | — | — | — | — | — | — | — | 5,151 | 5,151 | ||||||||||||
| Balance at June 30, 2025 | 1,952 | $ | — | 92,438,432 | $ | 92 | (258,425) | $ | (500) | $ | 509,171 | $ | (505,729) | $ | 3,034 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.